title: Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized.
abstract: BACKGROUND
  The most severe sequela of measles virus infection is subacute sclerosing panencephalitis (SSPE), a fatal disease of the central nervous system that generally develops 7-10 years after infection. From 1989 through 1991, a resurgence of measles occurred in the United States, with 55,622 cases of measles reported. The purpose of the present study was to identify cases of SSPE that were associated with the resurgence of measles and to calculate the risk of developing SSPE.
  
  
  METHODS
  Brain tissue samples obtained from 11 patients with a presumptive diagnosis of SSPE were tested for the presence of measles virus RNA. Measles virus genotypes were determined by reverse-transcription polymerase chain reaction (RT-PCR) and by analysis of the sequences of the PCR products. A search of the literature was conducted to identify reports of cases of SSPE in persons residing in the United States who had measles during 1989-1991.
  
  
  RESULTS
  The measles virus sequences derived from brain tissue samples obtained from 11 patients with SSPE confirmed the diagnosis of SSPE. For 5 of the 11 patients with SSPE who had samples tested by RT-PCR and for 7 patients with SSPE who were identified in published case reports, it was determined that the development of SSPE was associated with the measles resurgence that occurred in the United States during 1989-1991. The estimated risk of developing SSPE was 10-fold higher than the previous estimate reported for the United States in 1982.
  
  
  CONCLUSIONS
  Vaccination against measles prevents more cases of SSPE than was originally estimated.
authors.affiliation: Respiratory and Enteric Viruses Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
authors.forename: William J
authors.initials: WJ
authors.lastname: Bellini
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Rota
authors.forename: Luis E
authors.initials: LE
authors.lastname: Lowe
authors.forename: Russell S
authors.initials: RS
authors.lastname: Katz
authors.forename: Paul R
authors.initials: PR
authors.lastname: Dyken
authors.forename: Sherif R
authors.initials: SR
authors.lastname: Zaki
authors.forename: Wun-Ju
authors.initials: WJ
authors.lastname: Shieh
authors.forename: Paul A
authors.initials: PA
authors.lastname: Rota
mesh_terms: D000293:Adolescent; D000328:Adult; D001921:Brain / Q000821:virology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D008457:Measles / Q000150:complications / Q000209:etiology / Q000517:prevention & control* / Q000821:virology; D008458:Measles Vaccine / Q000008:administration & dosage*; D008459:Measles virus / Q000145:classification / Q000235:genetics / Q000276:immunology*; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000032:analysis; D013344:Subacute Sclerosing Panencephalitis / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination
chemical_list: D008458:Measles Vaccine; D012367:RNA, Viral